Mahamaya Lifesciences Limited has received board approval to extend the timeline for deploying its unutilised Initial Public Offer proceeds to March 31, 2028. The decision, approved through a circular resolution on March 10, 2026, addresses technical execution factors affecting the implementation of the company's manufacturing projects.

IPO Proceeds Utilisation Status

The company's IPO proceeds utilisation presents a clear picture of current deployment and remaining funds:

The company confirmed that there is no change or variation in the objects of the issue as stated in the prospectus, with the approval pertaining solely to rescheduling the implementation timeline for deployment of remaining funds.

Technical Execution Factors

The revised timeline addresses several project execution considerations that have impacted the original deployment schedule. The company received net IPO proceeds in November 2025, resulting in a limited execution window during Financial Year 2025-26 for implementing capital expenditure projects involving integrated manufacturing facilities.

The implementation of proposed projects, particularly the new Technical Manufacturing Plant, involves multiple sequential and interdependent stages. These include:

• Detailed engineering design and civil structural development
• Procurement of specialised plant and machinery
• Installation of utilities and electrification systems
• Equipment erection, alignment, and trial runs
• System stabilisation, validation, and final commissioning

Enhanced Project Configuration

Based on technical evaluation and engineering assessment, the company has incorporated enhancements in plant configuration, machinery specifications, and certain civil and structural components. These improvements are designed to enhance operational efficiency, scalability, and compliance standards.

The procurement process for specialised plant and machinery involves comprehensive cycles including engineering finalisation, manufacturing lead time, inspection, dispatch, installation, and commissioning. This necessitates phased vendor engagement and execution sequencing to ensure optimal configuration and integration of systems.

Compliance and Future Reporting

The company maintains its unutilised IPO proceeds in compliance with applicable provisions of the Companies Act, 2013, and SEBI regulations. The funds are temporarily parked in permitted interest-bearing instruments pending deployment.

Mahamaya Lifesciences confirmed that the rescheduled implementation timeline aligns with industry-standard execution cycles for integrated manufacturing facilities of comparable scale and complexity. The company will continue disclosing IPO proceeds utilisation in accordance with Regulation 32 of SEBI LODR Regulations, including review by the Audit Committee and reporting by the Monitoring Agency.

Mahamaya lifesciences Limited has withdrawn its participation from a major investor conference due to scheduling conflicts and business priorities. The company formally notified the Bombay Stock Exchange of this decision through a regulatory filing on March 9, 2026.

Conference Withdrawal Details

The pharmaceutical company was originally scheduled to participate in the Arihant Capital Bharat Connect Virtual Conference Rising Star 2026. However, the management decided to withdraw from the event citing internal scheduling constraints and ongoing business priorities that required immediate attention.

Regulatory Compliance

The withdrawal was communicated to the stock exchange in compliance with Regulation 30 of SEBI (LODR) Regulations, 2015, which mandates disclosure of material events and information. The company had previously informed the exchange about its participation plans on March 5, 2026, making the withdrawal notification necessary to maintain transparency with investors and regulatory authorities.

Management Communication

Managing Director Krishnamurthy Ganesan signed the official communication to the Bombay Stock Exchange, emphasizing that the decision was driven by internal operational requirements. The company assured that this withdrawal was purely due to scheduling conflicts rather than any fundamental business concerns.

The notification serves to keep investors and stakeholders informed about changes in the company's investor engagement activities, maintaining the transparency standards required under securities regulations.